Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026

Rhea-AI Summary

Anavex Life Sciences (Nasdaq: AVXL) will release fiscal 2026 first-quarter financial results on Monday, February 9, 2026. Management will host a conference call and live webcast on that day at 8:30 am ET to review results and recent corporate developments.

Investors can join via Anavex’s website or by phone (U.S. dial-in 1 929 205 6099; Meeting ID 844 4149 6344; passcode 789539). A replay will be available on the company website for up to 30 days.

News Market Reaction – AVXL

-2.88% 1.9x vol

1 alert

-2.88% News Effect

-$11M Valuation Impact

$369M Market Cap

1.9x Rel. Volume

On the day this news was published, AVXL declined 2.88%, reflecting a moderate negative market reaction. This price movement removed approximately $11M from the company's valuation, bringing the market cap to $369M at that time. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings date: February 9, 2026 Call time: 8:30 am ET US dial-in: 1 929 205 6099 +3 more

6 metrics

Earnings date February 9, 2026 Fiscal 2026 Q1 results release

Call time 8:30 am ET Conference call on February 9, 2026

US dial-in 1 929 205 6099 Conference call access number for U.S. participants

Meeting ID 844 4149 6344 Access ID for the February 9, 2026 conference call

Passcode 789539 Conference call passcode

Replay duration 30 days Time replay will remain available on company website

Market Reality Check

Price: $4.36 Vol: Volume 1,381,069 vs 20-da...

normal vol

$4.36 Last Close

Volume Volume 1,381,069 vs 20-day average 1,428,169, showing activity near typical levels ahead of the call. normal

Technical Shares at $4.52, trading below 200-day MA of $7.88 and 67.69% below the 52-week high, yet 58.04% above the 52-week low.

Peers on Argus

AVXL fell 3.83% while close biotech peers showed mixed moves: GERN up 14.07%, TN...

AVXL fell 3.83% while close biotech peers showed mixed moves: GERN up 14.07%, TNGX up 2.75%, PRAX up 0.55%, AVBP up 1.8%, and ZBIO down 0.98%, pointing to stock-specific trading rather than a uniform sector move.

Common Catalyst One peer, TNGX, reported participation in a biotech summit, but there is no broad, shared catalyst across peers matching this earnings-date announcement.

Previous Earnings date Reports

1 past event · Latest: Nov 18 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Nov 18	Earnings date notice	Neutral	-2.2%	Scheduled fiscal 2025 Q4 and year-end results with webcast and Q&A details.

Pattern Detected

The prior earnings-date announcement in November 2025 was followed by a modest negative 2.23% move, suggesting these scheduling updates have not historically driven sustained upside.

Recent Company History

This announcement sets the timetable for fiscal 2026 Q1 results and a conference call, echoing the prior earnings-date release on November 18, 2025, which outlined fiscal 2025 year-end reporting plans and an 8:30 am ET webcast. Since then, AVXL has reported a CHMP negative opinion in Europe and pursued re-examination, while securing FDA engagement and joining the ACCESS-AD initiative. Against that backdrop, the current notice mainly signals the next formal update on financials and corporate progress.

Historical Comparison

+2.2% avg move · In the past 12 months, AVXL issued 1 prior earnings-date notice with an average move of 2.23%. Today...

earnings date

+2.2%

Average Historical Move earnings date

In the past 12 months, AVXL issued 1 prior earnings-date notice with an average move of 2.23%. Today’s update arrives as shares trade 67.69% below the 52-week high, underscoring a weaker backdrop into this earnings cycle.

The company continues its pattern of pre-announcing earnings dates with webcast and dial-in details, providing a recurring cadence for updates on financials and recent corporate milestones.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-07-14

An active S-3 shelf dated 2025-07-14 remains in place, with expiration on 2028-07-14. It is not yet effective and shows 1 recorded 424B5 usage event, indicating the company has established but only partially utilized a registered capital-raising framework.

Market Pulse Summary

This announcement sets the date and access details for Anavex’s fiscal 2026 Q1 results on February 9...

Analysis

This announcement sets the date and access details for Anavex’s fiscal 2026 Q1 results on February 9, 2026, including an 8:30 am ET conference call and webcast with a 30-day replay. It follows a consistent pattern of pre-announcing earnings calls, giving investors a clear point for updates on financials and recent clinical and regulatory developments. Given the stock’s position well below its 52-week high, many will watch this call for clarity on progress and capital plans, including any use of its existing shelf registration.

Key Terms

central nervous system, cns, rett syndrome

3 terms

central nervous system medical

"and other central nervous system (CNS) disorders, today announced that it will"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

cns medical

"and other central nervous system (CNS) disorders, today announced that it will"

CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.

rett syndrome medical

"rare diseases, including Rett syndrome, and other central nervous system (CNS)"

A rare genetic disorder that disrupts normal brain development in young children, most commonly girls, leading to slowed growth, loss of purposeful hand use, repetitive hand movements, motor problems, speech loss, and cognitive and breathing irregularities. Investors watch it because its severity and few treatment options create clear medical need and potential markets for therapies; think of it as a broken traffic signal in the brain that, if fixed, could restore many downstream functions.

AI-generated analysis. Not financial advice.

Webcast and Conference Call To be Held Monday, February 9, 2026, 8:30 am ET

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its first quarter of fiscal 2026 on Monday, February 9, 2026.

Management will host a conference call on Monday February 9, at 8:30 am ET to review financial results and discuss recent corporate developments. Following management’s remarks, there will be a question-and-answer session.

Webcast / Conference Call Information:

The live webcast of the conference call will be available on Anavex’s website at www.anavex.com.

The conference call can be also accessed by dialing 1 929 205 6099 for participants in the U.S. using the Meeting ID# 844 4149 6344 and reference passcode 789539. A replay of the conference call will be available on Anavex’s website for up to 30 days.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com

Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com

FAQ

When will Anavex (AVXL) announce fiscal 2026 Q1 results and hold the conference call?

Anavex will announce fiscal 2026 Q1 results on Monday, February 9, 2026 at 8:30 am ET. According to the company, management will present results, discuss recent developments, and hold a question-and-answer session after prepared remarks.

How can investors access the Anavex (AVXL) February 9, 2026 webcast and conference call?

Investors can access the live webcast on Anavex’s website or dial 1 929 205 6099 (U.S.) with Meeting ID 844 4149 6344. According to the company, the webcast link and dial-in are provided for real-time participation.

Will Anavex (AVXL) provide a replay of the February 9, 2026 conference call and for how long?

Yes. A replay of the conference call will be available on Anavex’s website for up to 30 days after the call. According to the company, the replay ensures investors who miss the live event can review the discussion.

What topics will Anavex (AVXL) management cover during the February 9, 2026 call?

Management will review the company’s fiscal Q1 2026 financial results and discuss recent corporate developments. According to the company, remarks will be followed by a question-and-answer session for investor inquiries.

What phone details do U.S. participants need to join the Anavex (AVXL) conference call on February 9, 2026?

U.S. participants can dial 1 929 205 6099 and use Meeting ID 844 4149 6344 with passcode 789539. According to the company, these credentials allow live audio access to the management presentation and Q&A.